These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 12231516

  • 1. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G.
    Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
    [Abstract] [Full Text] [Related]

  • 2. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N.
    Cancer J Sci Am; 1997 Dec 20; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
    Cui CL, Chi ZH, Yuan XQ, Lian HY, Si L, Guo J.
    Ai Zheng; 2008 Aug 20; 27(8):845-50. PubMed ID: 18710619
    [Abstract] [Full Text] [Related]

  • 9. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.
    Cancer; 2004 Aug 01; 101(3):596-603. PubMed ID: 15274073
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 12. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun 15; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 15; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 14. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct 15; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

  • 15. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P.
    J Immunotoxicol; 2008 Apr 15; 5(2):201-7. PubMed ID: 18569391
    [Abstract] [Full Text] [Related]

  • 16. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Buzaid AC, Legha SS.
    Semin Oncol; 1994 Dec 15; 21(6 Suppl 14):23-8. PubMed ID: 7992096
    [Abstract] [Full Text] [Related]

  • 17. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S.
    Anticancer Drugs; 2008 Feb 15; 19(2):201-7. PubMed ID: 18176117
    [Abstract] [Full Text] [Related]

  • 18. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 19. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC.
    Br J Cancer; 2000 Jul 01; 83(1):16-21. PubMed ID: 10883662
    [Abstract] [Full Text] [Related]

  • 20. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L, Zeuli M, Sega FM, Cognetti F.
    J Exp Clin Cancer Res; 2000 Mar 01; 19(1):21-34. PubMed ID: 10840932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.